Chest Medicine (all articles)
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Clinical Determinants for Fatality of 44,672 Patients with COVID-19
1 May, 2020 | 02:48h | UTCClinical determinants for fatality of 44,672 patients with COVID-19 – Critical Care
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
COVID-19 and Its Implications for Thrombosis and Anticoagulation
30 Apr, 2020 | 04:13h | UTCCOVID-19 and its implications for thrombosis and anticoagulation – Blood
Perspective: What Policy Makers Need to Know About COVID-19 Protective Immunity
29 Apr, 2020 | 05:19h | UTCWhat policy makers need to know about COVID-19 protective immunity – The Lancet
Related: What Covid-19 antibody tests say — and don’t say — about immunity – Vox AND The False Hope of Antibody Tests – The Atlantic AND What Antibody Studies Can Tell You — and More Importantly, What They Can’t – ProPublica AND What if immunity to covid-19 doesn’t last? – MIT Technology Review AND Beware of Antibody-based COVID-19 “Immunity Passports” – Scientific American AND Coronavirus immunity: Can you catch it twice? – BBC
Related Commentary on Twitter
An especially astute and succinct essay on #COVID19 protective immunity @TheLancet todayhttps://t.co/HFGUGPdson
highlights unknowns on duration, role of T lymphocytes, what constitutes real protection, and herd immunity features pic.twitter.com/oBC48DcGCl— Eric Topol (@EricTopol) April 28, 2020
Case Series: Characterization of Ischemic Cutaneous Lesions Associated with Covid-19
29 Apr, 2020 | 05:14h | UTCSee also: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND From ‘COVID Toes’ to Hives, These Are the Skin Conditions Dermatologists Think Could Be Signs of Coronavirus – TIME
Lung Pathology of COVID-19: Is AFOP in Play?
29 Apr, 2020 | 04:58h | UTCLung pathology of COVID-19: is AFOP in play? – PulmCrit
Why Don’t Some Coronavirus Patients Sense their Alarmingly Low Oxygen Levels?
29 Apr, 2020 | 05:11h | UTCWhy don’t some coronavirus patients sense their alarmingly low oxygen levels? – Science
Patients with Cancer More Vulnerable to SARS-COV-2
29 Apr, 2020 | 05:00h | UTCCommentaries: COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows – AJMC AND Patients with blood and lung cancers are three times more at risk of dying of coronavirus than people with other tumors, study finds – Daily Mail AND Coronavirus: Cancer patients nearly three times more likely to die of Covid-19, study says – Independent
BTS Guideline for the Use of Long-term Macrolides in Adults with Respiratory Disease
29 Apr, 2020 | 04:49h | UTC
Systematic Review: Antidepressants for Smoking Cessation
29 Apr, 2020 | 04:40h | UTCAntidepressants for smoking cessation – Cochrane Library
Summary: Do medicines used to treat depression help people to quit smoking? – Cochrane Library
Report: Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19
28 Apr, 2020 | 04:45h | UTC
IDSA Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19
28 Apr, 2020 | 04:47h | UTC
Aerodynamic Analysis of SARS-CoV-2 in Two Wuhan Hospitals
28 Apr, 2020 | 04:36h | UTCAerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals – Nature
Commentary: SARS-CoV-2 Found in Aerosols in Hospital Staff Areas, Public Places – NEJM Journal Watch AND Coronavirus Lingers in Air of Crowded Spaces, New Study Finds – Bloomberg AND Expert reaction to a Nature paper presenting evidence for the presence of SARS-CoV-2 RNA in the air – Science Media Centre
Study: COVID-19 and Risks Posed to Personnel During Endotracheal Intubation
28 Apr, 2020 | 04:40h | UTCEditorial: COVID-19 and Risks Posed to Personnel During Endotracheal Intubation – JAMA
Twitter-based Learning for Continuing Medical Education? A New Perspective for a Paradigm Shift in Medical Education, Accelerated by COVID-19
28 Apr, 2020 | 04:28h | UTCRelated: How Twitter is Changing Medical Research (texts on the subject)
Richard Lehman’s Covid-19 Reviews—27 April 2020
28 Apr, 2020 | 04:21h | UTCRichard Lehman’s covid-19 reviews, 27 April 2020 – The BMJ Opinion
“In this weekly round-up, Richard Lehman looks at a personal selection of articles of relevance to clinicians dealing with covid-19”
Closely Watched Arthritis Drug Disappoints as a Covid-19 Treatment, Studies Show
28 Apr, 2020 | 04:18h | UTCClosely watched arthritis drug disappoints as a Covid-19 treatment, studies show – STAT
Clinical Practice: Mild or Moderate Covid-19
26 Apr, 2020 | 21:35h | UTCMild or Moderate Covid-19 – New England Journal of Medicine
Management of COVID-19 Respiratory Distress
26 Apr, 2020 | 21:36h | UTCManagement of COVID-19 Respiratory Distress – JAMA
Related Podcast: Coronavirus (COVID-19) Update: Ventilatory Management for COVID-Related Respiratory Failure – JAMA
Related Commentary on Twitter
Treatment guidelines for #ARDS still guide the care of critically ill #COVID19 patients, including conservative fluid strategies for patients without shock, lung-protective ventilation, prone positioning, and consideration of ECMO for refractory #hypoxemia https://t.co/7G0WoTiUQl
— JAMA (@JAMA_current) April 24, 2020
Study: The QT Interval in Patients with COVID-19 Treated with Hydroxychloroquine and Azithromycin
26 Apr, 2020 | 21:18h | UTC
FDA Safety Alert: Risk of Heart Rhythm Problems with the use of Hydroxychloroquine or Chloroquine for COVID-19
26 Apr, 2020 | 21:20h | UTCNews Release: FDA warning for Hydroxychloroquine or Chloroquine for COVID-19: Risk of Heart Rhythm Problems – Outbreak News Today
Respiratory Support in Novel Coronavirus Disease (COVID-19) Patients, with a Focus on Resource-Limited Settings
24 Apr, 2020 | 03:48h | UTC
Observational Study: Renin-Angiotensin System Inhibitors are Not Associated with Severity or Mortality in Hospitalized Patients with Coronavirus Disease
24 Apr, 2020 | 03:46h | UTCCommentary: Drugs for high blood pressure don’t appear to make COVID-19 worse – Science News